<iframe width=”560″ height=”315″ src=”https://www.youtube.com/embed/mOETFq1fNME?si=AyuUGfqAcsVHBHa9″ title=”YouTube video player” frameborder=”0″ allow=”accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share” referrerpolicy=”strict-origin-when-cross-origin” allowfullscreen></iframe>

The consortium, which included HALIX among other distinguished partners, achieved an unprecedented milestone by supplying over 3 billion doses of the ChAdOx1 COVID-19 vaccine in record time, saving over 6 million lives worldwide. Leveraging state-of-the-art cell culture technologies, streamlined workflows, and rigorous quality control processes, the team set new benchmarks in pharmaceutical manufacturing, process development, and technology transfer.

Dennis Verbart, Senior Director of Science and Technology at HALIX, stated: “Being part of this pioneering team was an incredible experience. The collective effort, flexibility and innovation showcased the power of collaboration in tackling global health challenges. We are proud that our contributions helped to deliver such impactful results.”

HALIX joined the consortium at the beginning of 2020 as one of the early partners, focusing on scaling up and optimizing the production process for the ChAdOx1 nCOVID-19 vaccine and producing clinical trial material. In December 2020, HALIX signed an agreement with AstraZeneca for the large-scale commercial manufacturing of the vaccine’s drug substance. Over the course of a year, HALIX produced enough commercial batches to cover over 80 million vaccine doses.

The MacRobert Award, presented by the Royal Academy of Engineering, acknowledges engineering innovation that demonstrates exceptional technical, social, and economic impact. This year’s finalists underscore the importance of collaborative efforts in achieving remarkable advancements in engineering and technology.

HALIX extends heartfelt congratulations to the University of Oxford, AstraZeneca, and all consortium partners involved. We remain committed to contributing to groundbreaking projects that drive significant positive change in global health.

More information is available here: https://macrobertaward.raeng.org.uk/previous-winners-and-finalists/2024-finalists

About HALIX

HALIX B.V. is a biopharmaceutical CDMO for biologics, enabling the treatment and prevention of life-threatening diseases. The company is focused on mammalian expression systems for the production of viral vectors and recombinant proteins. HALIX leverages scalable single-use, state-of-the-art bioprocessing technologies to provide its customers with services for the development and GMP manufacturing of drug substances and drug products. HALIX has entered into a number of contracts for the production of oncolytic immunotherapies and vaccines, utilizing innovative technologies, most notably the large-scale commercial drug substance manufacture of AstraZeneca’s COVID-19 vaccine. The company opened its state-of-the-art 6,700 m² GMP manufacturing facility in 2019, offering 1,000L SUB capacities, at the Leiden Bio Science Park, the Netherlands. HALIX is part of the family-owned Droege Group AG.

More information is available here: https://macrobertaward.raeng.org.uk/previous-winners-and-finalists/2024-finalists

The post HALIX Part of Leading Innovator Consortium for 2024 MacRobert Award appeared first on Halix | Bioscience as a service.

<iframe width=”560″ height=”315″ src=”https://www.youtube.com/embed/mOETFq1fNME?si=AyuUGfqAcsVHBHa9″ title=”YouTube video player” frameborder=”0″ allow=”accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share” referrerpolicy=”strict-origin-when-cross-origin” allowfullscreen></iframe>

The consortium, which included HALIX among other distinguished partners, achieved an unprecedented milestone by supplying over 3 billion doses of the ChAdOx1 COVID-19 vaccine in record time, saving over 6 million lives worldwide. Leveraging state-of-the-art cell culture technologies, streamlined workflows, and rigorous quality control processes, the team set new benchmarks in pharmaceutical manufacturing, process development, and technology transfer.

Dennis Verbart, Senior Director of Science and Technology at HALIX, stated: “Being part of this pioneering team was an incredible experience. The collective effort, flexibility and innovation showcased the power of collaboration in tackling global health challenges. We are proud that our contributions helped to deliver such impactful results.”

HALIX joined the consortium at the beginning of 2020 as one of the early partners, focusing on scaling up and optimizing the production process for the ChAdOx1 nCOVID-19 vaccine and producing clinical trial material. In December 2020, HALIX signed an agreement with AstraZeneca for the large-scale commercial manufacturing of the vaccine’s drug substance. Over the course of a year, HALIX produced enough commercial batches to cover over 80 million vaccine doses.

The MacRobert Award, presented by the Royal Academy of Engineering, acknowledges engineering innovation that demonstrates exceptional technical, social, and economic impact. This year’s finalists underscore the importance of collaborative efforts in achieving remarkable advancements in engineering and technology.

HALIX extends heartfelt congratulations to the University of Oxford, AstraZeneca, and all consortium partners involved. We remain committed to contributing to groundbreaking projects that drive significant positive change in global health.

More information is available here: https://macrobertaward.raeng.org.uk/previous-winners-and-finalists/2024-finalists

About HALIX

HALIX B.V. is a biopharmaceutical CDMO for biologics, enabling the treatment and prevention of life-threatening diseases. The company is focused on mammalian expression systems for the production of viral vectors and recombinant proteins. HALIX leverages scalable single-use, state-of-the-art bioprocessing technologies to provide its customers with services for the development and GMP manufacturing of drug substances and drug products. HALIX has entered into a number of contracts for the production of oncolytic immunotherapies and vaccines, utilizing innovative technologies, most notably the large-scale commercial drug substance manufacture of AstraZeneca’s COVID-19 vaccine. The company opened its state-of-the-art 6,700 m² GMP manufacturing facility in 2019, offering 1,000L SUB capacities, at the Leiden Bio Science Park, the Netherlands. HALIX is part of the family-owned Droege Group AG.

More information is available here: https://macrobertaward.raeng.org.uk/previous-winners-and-finalists/2024-finalists

The post HALIX Part of Leading Innovator Consortium for 2024 MacRobert Award appeared first on Halix | Bioscience as a service.

The post HALIX Appoints Dr. Lutz Hilbrich as New Chief Executive Officer appeared first on Halix | Bioscience as a service.

Leiden (The Netherlands, 10.07.2024) – HALIX is proud to announce its role as a consortium partner in the groundbreaking initiative led by the University of Oxford and AstraZeneca, recently named a finalist for the prestigious 2024 MacRobert Award. This recognition celebrates the collaborative effort and engineering excellence that enabled the global scale-up and manufacturing of the ChAdOx1 COVID-19 vaccine.

The consortium, which included HALIX among other distinguished partners, achieved an unprecedented milestone by supplying over 3 billion doses of the ChAdOx1 COVID-19 vaccine in record time, saving over 6 million lives worldwide. Leveraging state-of-the-art cell culture technologies, streamlined workflows, and rigorous quality control processes, the team set new benchmarks in pharmaceutical manufacturing, process development, and technology transfer.

Dennis Verbart, Senior Director of Science and Technology at HALIX, stated: “Being part of this pioneering team was an incredible experience. The collective effort, flexibility and innovation showcased the power of collaboration in tackling global health challenges. We are proud that our contributions helped to deliver such impactful results.”

HALIX joined the consortium at the beginning of 2020 as one of the early partners, focusing on scaling up and optimizing the production process for the ChAdOx1 nCOVID-19 vaccine and producing clinical trial material. In December 2020, HALIX signed an agreement with AstraZeneca for the large-scale commercial manufacturing of the vaccine’s drug substance. Over the course of a year, HALIX produced enough commercial batches to cover over 80 million vaccine doses.

The MacRobert Award, presented by the Royal Academy of Engineering, acknowledges engineering innovation that demonstrates exceptional technical, social, and economic impact. This year’s finalists underscore the importance of collaborative efforts in achieving remarkable advancements in engineering and technology.

HALIX extends heartfelt congratulations to the University of Oxford, AstraZeneca, and all consortium partners involved. We remain committed to contributing to groundbreaking projects that drive significant positive change in global health.

More information is available here: https://macrobertaward.raeng.org.uk/previous-winners-and-finalists/2024-finalists

About HALIX

HALIX B.V. is a biopharmaceutical CDMO for biologics, enabling the treatment and prevention of life-threatening diseases. The company is focused on mammalian expression systems for the production of viral vectors and recombinant proteins. HALIX leverages scalable single-use, state-of-the-art bioprocessing technologies to provide its customers with services for the development and GMP manufacturing of drug substances and drug products. HALIX has entered into a number of contracts for the production of oncolytic immunotherapies and vaccines, utilizing innovative technologies, most notably the large-scale commercial drug substance manufacture of AstraZeneca’s COVID-19 vaccine. The company opened its state-of-the-art 6,700 m² GMP manufacturing facility in 2019, offering 1,000L SUB capacities, at the Leiden Bio Science Park, the Netherlands. HALIX is part of the family-owned Droege Group AG.

More information is available here: https://macrobertaward.raeng.org.uk/previous-winners-and-finalists/2024-finalists

The post HALIX Part of Leading Innovator Consortium for 2024 MacRobert Award appeared first on Halix | Bioscience as a service.

Leiden (The Netherlands, 07.02.2023) – HALIX, a leading cGMP contract development and manufacturing organization (CDMO) specialized on viral vectors, vaccines and therapeutic proteins, today announced the appointment of Richard van Rijnsoever to lead the company’s business development, marketing, and project management strategy and functions. Richard will report directly to Alex Huybens, CEO of HALIX, and will be based out of the Company’s headquarters in Leiden, the Netherlands.

“We are excited to have Richard onboard as we embark on our next chapter of growth at HALIX. His extensive experience in the biopharmaceutical industry, specifically the CDMO space, makes him uniquely qualified for this role,” said Alex Huybens, CEO of HALIX. “Richard’s expertise and knowledge will be invaluable in driving commercial growth, ensuring project management excellence, and helping us reach our ambitious goals.”

With more than 25 years of experience in the biopharmaceutical CDMO space, Richard brings a unique blend of commercial and project management expertise. Most recently, he served at NRG|PALLAS, a global market leader in producing nuclear isotopes for diagnosis, therapy and nuclear research, where he worked on the business case for the new-to-build PALLAS reactor and was responsible for the establishment of a new department concerning the commercialization of several therapeutic isotopes.

Prior to that, he held the role of Director of Business Development and Project Management at SynCo Bio Partners (later acquired by Wacker Biotech), a leading CDMO with expertise in manufacturing live microbial biopharmaceuticals and in filling finished pharmaceuticals. There, Richard was responsible for business development, sales, and marketing, as well as the strategic development of the company, and was member of the Management Team.

He holds a degree in Medical Biology from the Vrije Universiteit Amsterdam and began his career at IntroGene, one of the pioneering companies developing and manufacturing viral-based products for gene therapy vectors and vaccines, later merged with U-Bisys to form Crucell (now Janssen Vaccines), where he worked for 9 years in various roles within R&D and later in Business Development.

“I am delighted to join the HALIX team and to have the opportunity to drive commercial growth and a build a strong market presence,” said Richard. “HALIX has an impressive track record in the industry, and I am looking forward to contribute to their mission.”

About HALIX

HALIX B.V. is a biopharmaceutical CDMO for biologics, enabling the treatment and prevention of life-threatening diseases. The company is focused on mammalian expression systems for the production of viral vectors and recombinant proteins. HALIX leverages scalable single-use, state-of-the-art bioprocessing technologies to provide its customers with services for the development and GMP manufacturing of drug substances and drug products. HALIX has entered into a number of contracts for the production of oncolytic immunotherapies and vaccines, utilizing innovative technologies, most notably the large-scale commercial drug substance manufacture of AstraZeneca’s COVID-19 vaccine. The company opened its state-of-the-art 6,700 m² GMP manufacturing facility in 2019, offering 1,000L SUB capacities, at the Leiden Bio Science Park, the Netherlands. HALIX is part of the family-owned Droege Group AG.

More information is available on: www.halix.nl

The post HALIX Appoints Richard van Rijnsoever as Vice President of Business Development and Project Management appeared first on Halix | Bioscience as a service.

Leiden (The Netherlands, 01.07.2021) – As of 1 July 2021, the Supervisory Board of the HAL Allergy Group has appointed Alex Huybens as Chief Executive Officer (CEO) and Member of the Board of HAL Allergy Holding B.V., as well as CEO of HALIX B.V.

Alex Huybens, Master of Business Administration (MBA) and with a degree in Engineering, started his career at HAL Allergy in 2003. In the following years, he took responsibility in several positions in Production, Supply Chain Management, Technical Services, Biochemistry, Microbiology and R&D functions.

“Alex Huybens is the right business leader for HAL Allergy and HALIX”, says Harry Flore, Chairman of the Supervisory Board of the Group and former CEO of the Company. “Alex Huybens has a proven track record of translating business opportunities into value-creating growth.”

Alex Huybens took over the role as Chief Operations Officer in the newly established HALIX B.V. creating a Contract Development and Manufacturing Organization (CDMO) for GMP-manufacturing of biologics for small- and midsized biotech companies as well as for big pharma (on BSL2 and BSL3-level). Today, HALIX is one of the leading European CDMOs producing drug substance/API for clinical trials as well as for commercial use, including the COVID-19 vaccine for AstraZeneca.

“In my role as CEO of HAL Allergy and HALIX, my focus will be on realizing the opportunities the markets are offering for us. While the further development of HALIX including the expansion
towards cell & gene therapy is on top of my list, HAL Allergy through its existing immunotherapies as well as its pipeline portfolio holds vast opportunities for us. By forming a bridge between both
companies, I want to be the number one contact for clients, partners as well as our employees.”

HAL Allergy specializes in the development, production and distribution of allergen immunotherapies for the treatment and prevention of allergic diseases. With a highly competitive product portfolio, including subcutaneous and sublingual products, and a future-oriented pipeline portfolio, HAL Allergy works intensively in collaboration with the world’s allergy specialists. Through its pipeline portfolio (including AIT candidates for food, especially peanut, in clinical and preclinical stage), HAL Allergy is well-positioned to meet its growth ambitions and enhance the quality of life for millions of people.

Alex Huybens, will head the Board of Directors of the HAL Allergy Group with the co-members Florian Rösch (CCFO), Dr. Hans van Schijndel (CRDO) and Gareth West (COO).

About HALIX

HALIX B.V. is a biopharmaceutical contract development and manufacturing organization (CDMO) for biologics enabling the treatment and prevention of life-threatening diseases. The company is focused on mammalian expression systems for the production of viral vectors and recombinant proteins. HALIX leverages scalable single-use, state-of-the-art bioprocessing technologies to provide its customers with services for the development and GMP manufacturing of drug substances and drug products. HALIX has entered into a number of contracts for the production of oncolytic immunotherapies and vaccines, utilizing innovative technologies. The company opened its state-of-the-art 6,700 m2 GMP manufacturing facility in 2019, offering 1,000L SUB capacities, at the Leiden Bio Science Park, the Netherlands. HALIX belongs to the family-owned Droege Group AG.
More information is available on: www.halix.nl

About HAL Allergy

HAL Allergy Group is active in the field of biopharmaceuticals and is located at the Bio Science Park in Leiden, The Netherlands. Our core business is the development and manufacturing of therapies and diagnostics for allergic diseases. With offices in major European countries, HAL Allergy is one of the European top players in the allergy immunotherapy business. Established in 1959 HAL Allergy has long experience in developing, producing and selling allergy therapies with an immuno-modulatory effect causing a reduction in symptoms and long-term disease suppression. The allergy therapies are used against common allergies such as hay fever, house dust mites allergy and allergic reactions towards wasp or bee stings. The main shareholder of HAL Allergy Group is Droege Group AG, based in Düsseldorf, Germany.
More information is available on: www.hal-allergy.com

The post Alex Huybens appointed as Chief Executive Officer (CEO) of HAL Allergy Holding B.V. and HALIX B.V. appeared first on Halix | Bioscience as a service.

Leiden, The Netherlands (01.04.2021) – HALIX B.V. is a contractor of AstraZeneca for large-scale commercial drug substance manufacture of AZD1222, AstraZeneca’s COVID-19 vaccine.

While discussions in the political arena are continuing, HALIX keeps on attracting media attention concerning AstraZeneca’s COVID-19 vaccine and the production of drug substance by HALIX for this vaccine.

Unfortunately, there is a lot of incorrect representation of facts in the media regarding the status of HALIX and its facility. HALIX and its facility have been successfully inspected by both IGJ and AstraZeneca on compliance with GMP, the international quality standards for (bio)pharmaceutical manufacturers. On top of that, the HALIX facility was authorized by the European Medicines Agency for the manufacture of the drug substance for the AstraZeneca vaccine. To achieve this in such a short and challenging period of time is in itself a huge accomplishment on the part of HALIX and the HALIX team.

HALIX is committed to continue its work for the manufacture of the drug substance for the AstraZeneca vaccine, support the vaccine production and combat COVID-19.

Because of our obligations towards AstraZeneca and our employees we cannot specifically respond to every news item or press inquiry. We refer to our press releases, issued on March 29^th and 26^th 2021.

About HALIX

HALIX B.V. is a biopharmaceutical contract development and manufacturing organization (CDMO) for biologics enabling the treatment and prevention of life threatening diseases. The company is focused on mammalian expression systems for the production of viral vectors and recombinant proteins. HALIX leverages scalable single-use, state-of-the-art bioprocessing technologies to provide its customers with services for the development and GMP manufacturing of drug substance and drug product. HALIX has entered into a number of contracts for the production of oncolytic immunotherapies and vaccines, utilizing innovative technologies. The company opened its state-of-the-art 6,700 m² GMP manufacturing facility in 2019, offering 1,000L SUB capacities, at the Leiden Bio Science Park, the Netherlands. HALIX belongs to the family owned Droege Group AG. More information is available on: www.halix.nl

Contact

Corporate Communications HALIX B.V.
Email: communications@www.halix.nl

The post Update On HALIX’s Commercial Manufacture Of COVID-19 Vaccine appeared first on Halix | Bioscience as a service.